福泰制药(VRTX)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 VRTX 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q1 2026
Item	Category	Value	YoY
Total revenues	revenue	2.99B	7.82%
Interest income, net	revenue	114.80M	-2.63%
Income from operations	profit	1.14B	80.62%
Total costs and expenses	cost	1.85B	-13.61%
Income before provision for income taxes	profit	1.25B	71.54%
Research and development expenses	cost	961.60M	-1.85%
Selling, general and administrative expenses	cost	493.70M	24.55%
Cost of sales	cost	392.80M	8.21%
Acquired in-process research and development expenses	cost	500000	-97.47%
Increase in fair value of contingent payments	cost	200000	-90.91%
Net income	profit	1.03B	59.59%
Provision for income taxes	cost	221.50M	163.38%

Business Breakdown
Segment	Value	YoY
Pharmaceuticals	2.99B	7.82%

Geography Breakdown
Segment	Value	YoY
UNITED STATES	1.78B	6.76%
Europe	950.00M	14.93%
Other Countries Outside of the United States and Europe	261.00M	-6.82%

Products Breakdown
Segment	Value	YoY
Product	2.99B	8.21%

Balance Sheet Q1 2026
Item	Category	Value
Cash and cash equivalents	assets	5.49B
Accounts receivable, net	assets	2.00B
Inventories	assets	1.77B
Marketable securities	assets	1.75B
Prepaid expenses and other current assets	assets	720.80M
Total current assets	assets	11.73B
Long-term marketable securities	assets	5.75B
Deferred tax assets	assets	2.95B
Operating lease assets	assets	1.69B
Property and equipment, net	assets	1.61B
Other assets	assets	1.26B
Goodwill	assets	1.09B
Other intangible assets, net	assets	418.50M
Total assets	assets	26.48B
Total liabilities	liabilities	7.12B
Total shareholders’ equity	equity	19.36B
Total current liabilities	liabilities	3.88B
Long-term operating lease liabilities	liabilities	1.99B
Other long-term liabilities	liabilities	1.26B
Retained earnings	equity	14.59B
Additional paid-in capital	equity	4.74B
Accumulated other comprehensive income (loss)	equity	24.80M
Common stock, value, issued	equity	2.50M
Accrued expenses	liabilities	2.98B
Accounts payable	liabilities	489.30M
Other current liabilities	liabilities	407.10M

Operating Activities – 3M 2026
Item	Value
Net income	1.03B
Increase (decrease) in prepaid expense and other assets	173.40M
Stock-based compensation expense	166.40M
Accrued expenses	70.50M
Depreciation and amortization expense	55.90M
Increase (decrease) in accounts receivable	39.80M
Accounts payable	35.60M
Other liabilities	23.10M
Other noncash income (expense)	-5.00M
Deferred income taxes	-65.30M
Increase (decrease) in inventories	-97.70M

Investing Activities – 3M 2026
Item	Value
Sales and maturities of available-for-sale debt securities	2.21B
Payments to acquire property, plant, and equipment	-133.40M
Payments to acquire debt securities, available-for-sale	-2.51B

Financing Activities – 3M 2026
Item	Value
Issuances of common stock under benefit plans	27.00M
Other financing activities	-400000
Payment, tax withholding, share-based payment arrangement	-228.50M
Payments for repurchase of common stock	-336.90M

Cash Balance – 3M 2026
Item	Value
Cash and cash equivalents, beginning of period	5.09B
Cash and cash equivalents, end of period	5.50B